Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Terminated 2Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3Thoracic 2Sarcoma 2Head & Neck 2Plasma cell 1Dermatologic 1CNS 1Breast 1

Conditions

Carcinoma, Renal Cell 2Sarcoma 1Lung Neoplasms 1Kidney Neoplasms 1Head and Neck Neoplasms 1Breast Neoplasms 1

Interventions

Docetaxel 191Gemcitabine 148Prednisone 142pembrolizumab 125enzalutamide 119Abiraterone Acetate 108Nivolumab 107Cisplatin 103Magnetic Resonance Spectroscopy 100Radiotherapy 95Sunitinib 94Leuprolide 91Carboplatin 82Specimen Handling 71Androgen Antagonists 63bicalutamide 60Radiosurgery 60Paclitaxel 59Goserelin 59Ipilimumab 57Bevacizumab 57apalutamide 53Sorafenib 53acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 51Everolimus 49cabozantinib 48abiraterone 46atezolizumab 45cabazitaxel 43durvalumab 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × AH 111585 × Genitourinary × Clear all
NCT01492192 2017-11-01

RGD-PET-CT in Cancer Angiogenesis

Oxford University Hospitals NHS Trust

Phase 2 Terminated
10 enrolled
Genitourinary

Carcinoma, Renal Cell

NCT01961583 2016-03-01

[18F]Fluciclatide PET Imaging of Pazopanib Response

Asan Medical Center

Phase 2 Terminated
12 enrolled
Genitourinary

Kidney Neoplasms

NCT00918281 2014-06-09

Reproducibility of 18F Uptake by Solid Tumors Using PET Imaging Following Intravenous Administration of (18F) Injection

GE Healthcare

Phase 2 Completed
70 enrolled 9 charts
BreastGenitourinaryHead & NeckSarcomaThoracic

Breast Neoplasms, Carcinoma, Renal Cell, Head and Neck Neoplasms, Lung Neoplasms, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡